Taylor Chartier

Taylor Chartier is a prominent figure in the fields of venture capital and artificial intelligence, currently serving as a Venture Analyst at Valley Capital Partners since April 2023. In addition to her role at Valley Capital, she is the Chief Executive Officer of Modicus Prime, a company she founded to leverage AI in pharmaceutical production and patient health.

Background and Education

Chartier has a strong educational background in engineering and artificial intelligence. She holds a Master of Science in Chemical Engineering from the University of Rochester and is pursuing a PhD in Artificial Intelligence Applications in Systems Biomedicine at the University of Luxembourg. Her academic pursuits focus on applying AI techniques to improve drug manufacturing processes, particularly for patients with conditions like Parkinson's disease.

Professional Experience

Before her current positions, Chartier accumulated extensive experience in the pharmaceutical industry:

• Worked as a data scientist and engineer at major companies such as Bayer Pharmaceuticals, where she supported FDA applications and implemented machine learning for process optimization.
• Held roles at Shire Pharmaceuticals and Emerald Therapeutics, focusing on manufacturing sciences and technology.

Modicus Prime

Chartier founded Modicus Prime during the COVID-19 pandemic, aiming to address systemic quality issues in drug production that result in significant financial losses for the pharmaceutical industry. The company specializes in AI-driven software solutions that enhance product quality and efficiency in drug manufacturing.

Contributions to Venture Capital

At Valley Capital Partners, Chartier focuses on backing AI and data-driven startups, particularly those innovating within the Midwest and Silicon Valley. Her expertise in both technology and pharmaceuticals positions her uniquely to identify promising ventures that can benefit from advanced computational techniques.

Summary

Taylor Chartier combines her engineering expertise with a passion for AI to drive innovation in pharmaceuticals and venture capital. Her leadership at Modicus Prime and analytical role at Valley Capital Partners reflect her commitment to improving healthcare through technology.